BRWA
BCRX icon

B. Riley Wealth Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

B. Riley Wealth Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,000
Closed -$80.3K – 1276
2024
Q2 		$80.3K Hold
13,000
– – ﹤0.01% 1322
2024
Q1 		$92K Hold
13,000
– – ﹤0.01% 1366
2023
Q4 		$77.9K Hold
13,000
– – ﹤0.01% 1337
2023
Q3 		$92K Hold
13,000
– – ﹤0.01% 1366
2023
Q2 		$91.5K Hold
13,000
– – ﹤0.01% 1444
2023
Q1 		$108K Buy
+13,000
New +$125K ﹤0.01% 1372

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

B. Riley Wealth Advisors's BCRX Position: Q3 2024 in Review

B. Riley Wealth Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 13,000 shares — an estimated $80.3K sold.

B. Riley Wealth Advisors first reported a position in BCRX in Q1 2023 and held it in 6 quarters. The position peaked at $108K in Q1 2023. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • B. Riley Wealth Advisors reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 13,000 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $80.3K.
  • B. Riley Wealth Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • B. Riley Wealth Advisors's BioCryst Pharmaceuticals position peaked at $108K in Q1 2023.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on B. Riley Wealth Advisors's 13F filing for Q3 2024, filed 13 Dec 2024.